Profile data is unavailable for this security.
About the company
Pliant Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering and developing therapies for the treatment of fibrosis and related diseases. Its lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). The Company has initiated BEACON-IPF, a Phase 2b trial of bexotegrast in IPF. It has also developed PLN-1474, a small molecule, selective inhibitor of αvß1 integrin for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis. It has initiated a Phase 1 study for its third clinical program, PLN-101095, a small molecule, dual-selective inhibitor of αvß8 and αvß1 integrins, that is being developed for the treatment of solid tumors. The Company has a preclinical program, PLN-101325, targeting muscular dystrophies.
- Revenue in USD (TTM)248.00k
- Net income in USD-170.74m
- Incorporated2015
- Employees158.00
- LocationPliant Therapeutics Inc260 Littlefield Avenue, Suite 150SOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (650) 481-6770
- Websitehttps://pliantrx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Emergent Biosolutions Inc | 1.19bn | -565.30m | 392.49m | 1.60k | -- | 0.5912 | -- | 0.3311 | -10.87 | -10.87 | 22.86 | 12.67 | 0.4988 | 1.99 | 6.09 | 740,875.00 | -23.79 | -2.94 | -38.89 | -3.66 | 41.19 | 53.24 | -47.69 | -5.95 | 0.5538 | 0.0636 | 0.5771 | -- | -6.10 | 6.05 | -259.40 | -- | -4.29 | -- |
| Theravance Biopharma Inc | 61.51m | -44.77m | 404.63m | 99.00 | -- | 1.97 | -- | 6.58 | -0.861 | -0.861 | 1.19 | 4.22 | 0.1352 | -- | 4.57 | 621,313.10 | -9.84 | -40.51 | -10.39 | -48.50 | -- | -- | -72.78 | -305.27 | -- | -- | 0.00 | -- | 11.84 | -0.9956 | 40.54 | -- | -19.24 | -- |
| Eyepoint Pharmaceuticals Inc | 50.02m | -78.92m | 417.20m | 121.00 | -- | 1.60 | -- | 8.34 | -1.83 | -1.83 | 1.17 | 5.01 | 0.2068 | 1.14 | 7.44 | 413,380.20 | -32.62 | -40.44 | -40.06 | -47.79 | 90.50 | 83.45 | -157.77 | -186.23 | 5.01 | -- | 0.00 | -- | 11.14 | -- | 30.77 | -- | -- | -- |
| Avid Bioservices Inc | 136.74m | -18.26m | 425.31m | 365.00 | -- | 2.36 | -- | 3.11 | -0.2888 | -0.2888 | 2.17 | 2.84 | 0.302 | 3.18 | 4.89 | 374,616.40 | -4.03 | 10.70 | -6.13 | 15.18 | 7.47 | 22.72 | -13.35 | 25.86 | 0.3097 | -2.71 | 0.4548 | 0.00 | 24.81 | 22.72 | -99.80 | -- | 82.98 | -- |
| Esperion Therapeutics Inc | 229.74m | -86.51m | 443.34m | 240.00 | -- | -- | -- | 1.93 | -1.00 | -1.00 | 1.76 | -1.57 | 0.7353 | 0.7415 | 5.05 | 957,250.00 | -27.69 | -69.45 | -47.42 | -101.81 | 81.85 | -- | -37.65 | -147.44 | 1.78 | -0.6581 | -- | -- | 54.14 | -- | 10.45 | -- | -- | -- |
| Annexon Inc | 0.00 | -120.74m | 472.40m | 70.00 | -- | 1.57 | -- | -- | -1.46 | -1.46 | 0.00 | 2.90 | 0.00 | -- | -- | 0.00 | -42.15 | -44.06 | -44.99 | -46.93 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.43 | -- | 62.56 | -- |
| Kalvista Pharmaceuticals Inc | 0.00 | -108.30m | 485.59m | 118.00 | -- | 4.50 | -- | -- | -3.14 | -3.14 | 0.00 | 2.56 | 0.00 | -- | -- | 0.00 | -68.23 | -33.56 | -75.55 | -36.55 | -- | -- | -- | -941.88 | -- | -- | 0.00 | -- | -- | -- | -12.83 | -- | -3.47 | -- |
| SNDL Inc | 661.23m | -99.79m | 496.86m | 2.52k | -- | 0.554 | -- | 0.7514 | -0.3812 | -0.39 | 2.53 | 3.39 | 0.5855 | 4.67 | 33.35 | 262,811.70 | -9.19 | -24.44 | -9.95 | -27.94 | 24.97 | 22.49 | -15.69 | -62.17 | 2.86 | -83.91 | 0.1157 | -- | 27.63 | -- | 49.83 | -- | -- | -- |
| SIGA Technologies Inc | 157.02m | 79.26m | 554.76m | 45.00 | 7.12 | 3.36 | 6.95 | 3.53 | 1.10 | 1.10 | 2.20 | 2.32 | 0.7354 | 0.3631 | 10.32 | 3,489,424.00 | 37.12 | 22.34 | 47.49 | 27.56 | 87.71 | 88.65 | 50.48 | 41.14 | 2.19 | -- | 0.00 | 29.51 | 26.31 | -21.75 | 100.76 | -30.57 | -26.67 | -- |
| Arbutus Biopharma Corp | 12.99m | -74.39m | 590.69m | 73.00 | -- | 4.92 | -- | 45.49 | -0.4393 | -0.4393 | 0.0766 | 0.6362 | 0.0761 | -- | 5.41 | 177,890.40 | -43.56 | -52.62 | -50.25 | -58.11 | -- | -- | -572.81 | -537.81 | -- | -- | 0.00 | -- | -53.51 | 25.00 | -4.89 | -- | -2.40 | -- |
| Pliant Therapeutics Inc | 248.00k | -170.74m | 639.45m | 158.00 | -- | 1.46 | -- | 2,578.44 | -2.86 | -2.86 | 0.0042 | 7.25 | 0.0004 | -- | 0.0701 | 1,569.62 | -30.50 | -33.24 | -32.04 | -35.39 | -- | -- | -68,847.98 | -360.29 | -- | -- | 0.0642 | -- | -83.69 | -- | -30.83 | -- | -16.89 | -- |
| Sinovac Biotech Ltd | 448.27m | -105.90m | 639.90m | 3.04k | -- | -- | -- | 1.43 | -1.08 | -1.08 | 4.19 | 87.41 | 0.0323 | 1.13 | 0.9175 | 147,602.60 | -1.86 | 36.14 | -2.80 | 58.37 | 59.51 | 90.77 | -57.63 | 65.87 | 10.18 | -- | 0.0207 | -- | -69.97 | 14.31 | -198.16 | -- | 91.80 | -- |
| Evolus Inc | 219.70m | -60.00m | 667.43m | 279.00 | -- | 35.99 | -- | 3.04 | -1.05 | -1.05 | 3.82 | 0.2962 | 1.14 | 3.86 | 7.62 | 804,750.90 | -31.06 | -40.92 | -40.14 | -59.74 | 69.28 | 65.43 | -27.31 | -80.46 | 2.96 | -2.90 | 0.8674 | -- | 35.98 | -- | 17.10 | -- | 182.77 | -- |
| PetIQ Inc | 1.12bn | 7.34m | 672.09m | 1.93k | 104.77 | 2.84 | 12.39 | 0.6001 | 0.2156 | 0.2156 | 36.40 | 7.95 | 1.29 | 4.58 | 5.67 | 579,376.60 | 0.8933 | -4.32 | 1.14 | -5.23 | 23.66 | 20.05 | 0.6951 | -3.66 | 1.25 | 1.84 | 0.6517 | -- | 19.58 | 15.83 | 104.42 | -- | 4.96 | -- |
| Phibro Animal Health Corp | 999.56m | 13.16m | 676.41m | 1.92k | 51.41 | 2.50 | 13.89 | 0.6767 | 0.3249 | 0.3249 | 24.68 | 6.67 | 1.03 | 2.42 | 6.37 | 520,606.30 | 1.35 | 5.46 | 1.66 | 6.83 | 30.33 | 31.41 | 1.32 | 5.11 | 1.67 | 2.26 | 0.6427 | 42.99 | 3.78 | 3.59 | -33.69 | -13.56 | 22.80 | 3.71 |
| Harrow Inc | 138.68m | -31.33m | 737.71m | 315.00 | -- | 12.18 | -- | 5.32 | -0.9079 | -0.9079 | 4.09 | 1.71 | 0.5406 | 4.21 | 6.75 | 440,244.40 | -12.21 | -10.86 | -13.79 | -12.71 | 69.77 | 70.75 | -22.59 | -15.35 | 2.75 | -0.3302 | 0.7536 | -- | 46.95 | 25.77 | -73.30 | -- | 143.88 | -- |
Data as of Jul 03 2024. Currency figures normalised to Pliant Therapeutics Inc's reporting currency: US Dollar USD
57.93%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Deep Track Capital LPas of 31 Mar 2024 | 5.75m | 9.53% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 4.15m | 6.88% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 3.92m | 6.50% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 3.81m | 6.32% |
| First Light Asset Management LLCas of 31 Mar 2024 | 3.53m | 5.86% |
| Laurion Capital Management LPas of 31 Mar 2024 | 3.47m | 5.76% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 3.34m | 5.53% |
| Redmile Group LLCas of 31 Mar 2024 | 3.10m | 5.13% |
| Polar Capital LLPas of 31 Mar 2024 | 2.02m | 3.34% |
| Great Point Partners LLCas of 31 Mar 2024 | 1.85m | 3.07% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
